Two new studies clarify how Epstein-Barr virus may trigger multiple sclerosis: one shows a doubled CD4+ T cell response in untreated patients, while another reveals EBV-activated B cells cause brain inflammation in mice. Insights point to potential therapies targeting EBV-specific immune activity.
Phase III FENtrepid trial results show investigational BTK inhibitor fenebrutinib met its primary endpoint of non-inferiority to ocrelizumab in primary progressive MS, with a 12% reduction in disability progression risk and strongest effect on upper limb function.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07483450 |
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT07282574 |
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) |
RECRUITING | PHASE2 |
| NCT06846281 |
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. |
RECRUITING | PHASE3 |
| NCT06780150 |
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) |
RECRUITING | |
| NCT05688436 |
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies |
ACTIVE_NOT_RECRUITING | |
| NCT05296161 |
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT05285891 |
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis |
RECRUITING | PHASE4 |
| NCT05269004 |
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05123703 |
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04688788 |
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis |
ACTIVE_NOT_RECRUITING | PHASE3 |
